Insider · CIK 0002088466
David Scott Moore
Files at CRVS (Corvus Pharmaceuticals, Inc.). First filing Jun 15, 2026, latest Jun 15, 2026.
In brief
David Scott Moore files SEC Form 4 as director at CRVS (Corvus Pharmaceuticals, Inc.). Since Jun 15, 2026, David Scott Moore has reported 1 open-market buy worth $250k and 0 open-market sells worth $0, the latest filed on Jun 15, 2026.
A track record needs three past buys with six months of prices behind them; David Scott Moore has 0, so none is measured yet.
The newest scored trade: bought $250k of CRVS on Jun 11, 2026, filed Jun 15, 2026, scored 44 (moderate). In the last 12 months: 1 buy worth $250k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRVS: Corvus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | CRVSbuy Corvus Pharmaceuticals, Inc. | $250k 21,700 shares | - | +211% from low-55% from high |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | CRVS Corvus Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +21,700 | $11.53 | $250k | 21,700 | Jun 15, 2026 |
| Jun 11, 2026 | CRVS Corvus Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 15, 2026 |
| Oct 2, 2025 | CRVS Corvus Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Oct 6, 2025 |
Questions about David Scott Moore
Answered from the filings on this page, as of the latest one.
Is David Scott Moore buying or selling?
In the last 12 months David Scott Moore reported 1 open-market buy worth $250k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $250k of CRVS on Jun 11, 2026. Grants, option exercises and tax withholding are not counted.
How did David Scott Moore's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Scott Moore has 0.
Where does David Scott Moore file Form 4?
David Scott Moore has filed Form 4 at CRVS (Corvus Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.